NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · SIBN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
SI-BONE, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
SI-BONE, Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$0.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SI-BONE, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 5, 2025 |
| -$0.15+37.5% vs estimate |
| $47.29M+1.24% vs estimate |
| Q4 2024 | Feb 24, 2025 | -$0.11+24.38% vs estimate | $49.00M+1.8% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.16+27.27% vs estimate | $40.34M-13.97% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $23.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
$30.41+$0.29 (+0.96%)
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 18.01% below the high.
$82.91+$1.65 (+2.03%)
Globus Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.23% below the high.
$11.37-$0.08 (-0.7%)
Alphatec Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.18% below the high.
$45.72-$0.04 (-0.09%)
CONMED Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.8% below the high.
